WHO announces the first non-exclusive license for an antibody test developed by COVID-19 or a vaccine (+ Video) ›Cuba› Granma

The Group of Access to the Technology COVID-19 of the World Health Organization (WHO) and the Group of Patents of Medicines reached, this 23 of November, a license agreement with the Higher Council of Scientific Research of Spain for a test of COVID-19 serological antibodies.

According to the United Nations website, this license agreement with Spain will allow the serological test – which verifies the presence of antibodies developed by the COVID-19 infection or by a vaccine – to reach the countries most in need, since tests are easy to use with a basic lab infrastructure.

The objective of the license, the first non-exclusive of a coronavirus-related health tool, is to facilitate the rapid manufacture and commercialization of that COVID-19 serological test worldwide.

The WHO explained that the test effectively checks for the presence of anti-SARS-COV-2 antibodies developed in response to a COVID-19 infection or a vaccine.

He also added the health entity that is easy to use in all settings with a basic laboratory infrastructure, such as those found in rural areas of low and middle income countries; and the results can be read with the naked eye compared to a color chart, although a specialized reader is recommended for greater precision.

In addition, the director of the WHO, Tedros Adhanom Ghebreyesus, praised the solidarity commitment of the Spanish Research Council in offering global access to its technology and knowledge.

“This is the kind of open and transparent license that we need to expand access during and after the pandemic. I urge developers of COVID-19 vaccines, treatments and diagnostics to follow this example to turn the tide of the pandemic and the devastating global inequality it has highlighted, “said the manager.

See also  Bars ask for clarity to request covid vaccination card

The UN publication also highlights that the agreement covers all the related patents and the biological material necessary for the manufacture of the test, as the Council will provide all the technical knowledge and train the Medicines Patent Group and potential licensees.

The license will be royalty-free for low- and middle-income countries and will remain valid until the expiration date of the last patent.

On the other hand, the Spanish Research Council highlighted the importance of seeking solutions so that technologies related to the COVID-19 pandemic in particular, and health in general, reach all countries, including those most in need.

So far, four different tests have been developed to detect the presence of the coronavirus in the human body, one of which has the potential to distinguish the immune response of people infected with COVID-19 from the response of vaccinated people.


Leave a Comment